Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2024 08:00 ET | Source: Entera Bio Ltd.

Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024

JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins,...
May 13, 2024 07:00 ET | Source: Entera Bio Ltd.

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today...
February 05, 2024 13:00 ET | Source: DelveInsight Business Research LLP

Hypoparathyroidism Market is Expected to Exhibit Impressive Growth by 2032, Assesses DelveInsight | Leading Companies Developing Therapies - Ascendis Pharma, Amolyt Pharma, Bridgebio, Calcilytix Therapeutics

New York, USA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Hypoparathyroidism Market is Expected to Exhibit Impressive Growth by 2032, Assesses DelveInsight | Leading Companies Developing Therapies - Ascendis...
March 07, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

CARMEL, Ind., March 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
January 24, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference

CARMEL, Ind., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
January 05, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

CARMEL, Ind., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
November 14, 2022 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs

CARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
October 05, 2022 09:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109

CARMEL, Ind., Oct. 05, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
July 26, 2022 12:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism

CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing precision endocrine peptide therapeutics to treat endocrine disorders,...
May 16, 2022 08:00 ET | Source: Entera Bio Ltd.

Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy

BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of...

Next Page keyboard_arrow_right